(b)(4) initial emdr submission.A follow up emdr will be submitted if additional information becomes available.(b)(4).No additional information was provided by defective medicines report centre.Primevigilance did reach out to obtain with no success.Should additional information be available in the future, the complaint will be re-opened and investigated.All complaints are reviewed during monthly quality/safety meetings.In addition, complaints are trended at monthly quality data analyst meetings and quarterly plant management review meetings.
|
Material no.: unknown.Batch no.: unknown.It was reported that the patient experienced an allergic reaction while using chloraprep.Per cioms on an unknown date, the patient received treatment with cutaneous chloraprep 2% (chlorhexidine gluconate, isopropyl alcohol).(product licence number was 05920/0002; expiry date: 01/06/2023).Dosing details, indication and batch number were not provided.On an unknown date, the patient experienced allergic reaction (llt: allergic reaction) during donation process.The area was slightly red, raised area lessened, and there was no tingling pain or itching.At the time of the report, action taken with chloraprep and the outcome of the event of allergic reaction were not provided.The reporter did not provide seriousness and causality assessments for the event of allergic reaction.No further information was provided.
|